Johnson & Johnson is facing a fresh round of marketing scrutiny, with federal and state investigators probing the promotion of top arthritis and hep C meds.

The FDA actually invited Mitsubishi Tanabe to file Radicava for U.S. approval based on data generated in Japan. Now, it's the first new ALS med in decades.

Already under pressure from lawsuits and Congress for its insulin pricing, Eli Lilly faces a pair of new state-level investigations.

AstraZeneca is officially on the board with checkpoint inhibitor Imfinzi, which nabbed its first FDA approval Monday.

Novartis got FDA approval today for Rydapt, its new breakthrough treatment for acute myeloid leukemia (AML), which is expected to generate more than $250…

Sanofi CEO Olivier Brandicourt has been criticized for failing to pull off a couple of big acquisitions, but his more mundane deal to get Boehringer Ingelheim’…

Johnson & Johnson has kept a positive attitude about its blockbuster immunology drug Remicade and the biosimilar competition it’s facing.

Analysts question whether positive survival data for Lilly's abemaciclib will be enough to help the third-to-market med hang with its competition.…

Regulatory